Search

Search Constraints

You searched for: Author/Creator Goyal, Vinod Kumar

Search Results

1. 0053 SUVN-G3031: Safety, Tolerability and Pharmacokinetics of a Potent and Selective Histamine H3 Receptor Inverse Agonist - Single and Multiple Ascending Doses in Healthy Subjects. (12th April 2019)

2. 0139 SUVN-G3031, A Potent and Selective Histamine H3 Receptor Inverse Agonist - Phase-2 Investigational New Drug for the Treatment of Narcolepsy - Differentiating Factors with Competitor Clinical Candidates. (12th April 2019)

4. [P1–063]: SUVN‐G3031, A SELECTIVE H3 RECEPTOR INVERSE AGONIST: ASSESSMENT OF SAFETY, TOLERABILITY AND PHARMACOKINETICS IN HEALTHY HUMAN VOLUNTEERS. (1st July 2017)

5. [P1–460]: SUVN‐D4010: A POTENT AND SELECTIVE 5‐HT4 RECEPTOR PARTIAL AGONIST— ASSESSMENT OF SAFETY, TOLERABILITY AND PHARMACOKINETICS IN HEALTHY HUMAN VOLUNTEERS. (1st July 2017)

6. [P2–033]: SUVN‐502 + DONEPEZIL + MEMANTINE (TRIPLE COMBINATION) REPRESENTS A PROMISING NEW APPROACH FOR SYMPTOMATIC TREATMENT OF ALZHEIMER's DISEASE. (1st July 2017)

9. Effect of Concurrent Use of Memantine on The Efficacy of Masupirdine (SUVN‐502): A Post‐hoc Analysis of a Phase‐2 Randomized Placebo‐Controlled Study. (20th December 2022)

10. Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study. Issue 1 (1st June 2022)